Using only information available through December 31, 2021, how would you allocate a hypothetical $10,000 across international (non-US) stocks heading into 2022's post-COVID, rising-rate environment? Cover the market backdrop as it was known then, give the allocation in dollars and percentages with the reasoning for each position, say what would change your mind, and state your most likely error.

Using only what was known through December 31, 2021: the S&P 500 closed at 4,766.18, up 26.9% for the year, while MSCI EAFE returned about 11% and MSCI Emerging Markets was actually negative at roughly -2.5%. That gap is the starting point for any non-US allocation. At its December 15 FOMC meeting the Fed doubled the taper pace to $30 billion a month, put asset purchases on track to end in March, and published a dot plot penciling in three 2022 hikes. November CPI had already printed 6.8% year over year on December 10, the hottest since 1982, with December tracking toward 7%. The ECB and BOJ declined to follow — the BOJ still pinning 10-year JGBs near zero under yield-curve control — and currencies priced the divergence: the euro fell from 1.2216 to 1.1370 across 2021, the yen from 103 to past 115. Weaker local currencies cut dollar returns on unhedged holdings, but they mechanically flatter exporters who invoice in dollars and pay costs in yen or won. That argues for a core in Asian export hardware, where the semiconductor shortage is a pricing tailwind rather than a cost. Taiwan Semiconductor (TSM), $1,800 — closed the year near $120, roughly 53% of global foundry revenue, NT$1.59 trillion (~$57 billion) in 2021 sales at gross margins above 50%, and spending ~$30 billion in capex including the $12 billion Arizona fab and the Kumamoto joint venture with Sony announced November 9. Samsung Electronics (005930.KS), $1,200 — 78,300 won at the December 30 close, near 10x forward earnings, DRAM and NAND leadership plus the $17 billion Taylor, Texas foundry announced November 23. Toyota (TM), $1,200 — the manufacturer that handled the chip shortage best thanks to the stockpiling discipline it adopted after 2011, now a direct beneficiary of a 115 yen, and on December 14 it committed ¥8 trillion to electrification with 30 BEVs by 2030. The balance hedges the rate shock rather than fighting it. TotalEnergies, $900 — Brent closed 2021 at $77.78, up roughly 50%, and European majors trade at single-digit multiples with real dividends. Mitsubishi UFJ, $700, near half of book value, is levered to any move off zero. Novo Nordisk, $900 (Wegovy approved June 4) and Nestlé, $800 supply pricing power and non-cyclical cash flow. BHP, $700 for commodity exposure. ASML, $800 is the one duration bet — an EUV monopoly, but a 2021 gain near 80% leaves a multiple that rising real rates can compress. China gets a deliberate $600 total, split across Alibaba and Tencent: Fitch declared Evergrande in default on December 9 against roughly $300 billion of liabilities, Didi announced its NYSE exit on December 3, Xi'an locked down 13 million people on December 23, and the Hang Seng fell 14% in 2021. Cheap is not the same as clearing. Remaining $400 in cash funds a second tranche if the hikes land harder than three. The asymmetry I am least sure of is Japan: a weaker yen helps Toyota's translated earnings while quietly taxing my dollar return on the same shares, and if the BOJ blinks, that trade reverses on both legs at once. This is a read of the available evidence, not a guaranteed outcome.

Smart overweight on Asian chip and export names; weak yen was a real structural tailwind and the chip shortage was imminent. Deliberately small China allocation given Evergrande's December 2021 trajectory is defensible. Novo Nordisk sizing feels arbitrary though — no catalyst named, so it reads like filler. Otherwise well-reasoned for the stated inputs.

The strongest critique I can make is that the currency logic looks double-counted: a weak yen flatters Toyota's translated export earnings, but a dollar investor holding a yen-denominated share eats the same depreciation on the way home, so the FX tailwind to earnings is substantially offset by the FX drag on returns unless the position is hedged — and the post appears to collect only the first half. Second, the diversification is nominal; TSMC, Samsung, ASML and to a degree Toyota are one semiconductor/export cycle, roughly half the book in a single factor, and after two years of shortage-driven ordering the double-booking and inventory risk means this could be the late cycle rather than the middle. Third, deliberately underweighting China doesn't actually reduce China exposure — BHP is close to a levered claim on Chinese property construction, which is precisely the Evergrande risk being avoided in the equity sleeve, and the Taiwan and Korea names route demand through the same customer. I'd also want the Fed in the reasoning, since the December dot plot and accelerated taper are already on the table and land hardest on the highest-multiple holdings here, ASML and Novo. Worth noting too that TSMC's strait risk isn't diversified by owning Samsung across another contested peninsula.

The China underweight aged well — Shanghai's brutal spring 2022 lockdown and the broader zero-COVID drag hammered Alibaba and Tencent well beyond what a $600 basket implied, so dodging deeper exposure there was the right call. The Asian chip overweight was the bigger miss: 2022 flipped the shortage into a glut just as the Fed's rate-hike cycle crushed growth multiples, and TSM, Samsung, and ASML all took steep double-digit drawdowns through the year rather than riding the weak yen higher. Speaking of which, the yen thesis was directionally right but overcooked as a Toyota tailwind — USD/JPY did blow out further, from around 115 to near 150, forcing the BOJ into its first FX intervention in decades, and while that currency move did cushion Toyota's export earnings and it outperformed the chip names, it still couldn't fully offset the global equity selloff. TotalEnergies was the standout call: Russia's February 2022 invasion sent energy prices spiking and European majors had a genuinely strong year, so that position did exactly what it was sized to do. Novo Nordisk turned out prescient but early — it was a solid holding through 2022, yet the real GLP-1/Wegovy-driven re-rating that made it one of Europe's biggest winners didn't fully ignite until 2023 and beyond, so the position captured the setup more than the payoff within this window.